Journal
CELL
Volume 179, Issue 5, Pages 1033-1055Publisher
CELL PRESS
DOI: 10.1016/j.cell.2019.10.017
Keywords
-
Categories
Funding
- NIH-YALE SPORE in Lung Cancer [P50CA196530]
- NCI Outstanding Investigator Award [R35CA231996, R35CA232105]
- Ludwig Center at Harvard
- Lungevity Foundation
- V Foundation for Cancer Research
- NCI Prostate SPORE [P50CA186786]
- Prostate Cancer Foundation
- Early Detection Research Network [UO1CA214170]
- [P50CA196530-03S1]
- [R01CA212649]
Ask authors/readers for more resources
For decades, research into cancer biology focused on the involvement of protein-coding genes. Only recently was it discovered that an entire class of molecules, termed non-coding RNA (ncRNA), plays key regulatory roles in shaping cellular activity. An explosion of studies into ncRNA biology has since shown that they represent a diverse and prevalent group of RNAs, including both oncogenic molecules and those that work in a tumor suppressive manner. As a result, hundreds of cancer-focused clinical trials involving ncRNAs as novel biomarkers or therapies have begun and these are likely just the beginning.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available